Kbc Group Nv Vanda Pharmaceuticals Inc. Transaction History

Kbc Group Nv

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Feb 15, 2024	SELL	$5.9 - $6.95 $13,811 - $16,269	-2,341 Reduced 42.7%	3,142 $21,000
Q1 2023 Feb 14, 2024	SELL	$6.18 - $7.99 $14,467 - $18,704	-2,341 Reduced 42.7%	3,142 $21,000
Q1 2023 May 04, 2023	SELL	$6.18 - $7.99 $14,467 - $18,704	-2,341 Reduced 42.7%	3,142 $21,000
Q3 2022 Feb 15, 2024	BUY	$9.44 - $11.76 $51,759 - $64,480	5,483 New	5,483 $54,000
Q2 2022 Feb 14, 2024	SELL	$9.31 - $11.84 $50,171 - $63,805	-5,389 Reduced 49.57%	5,483 $60,000
Q2 2022 Jul 26, 2022	SELL	$9.31 - $11.84 $50,171 - $63,805	-5,389 Reduced 49.57%	5,483 $60,000
Q1 2022 Feb 14, 2024	SELL	$10.84 - $16.55 $110,437 - $168,611	-10,188 Reduced 48.38%	10,872 $123,000
Q1 2022 May 06, 2022	SELL	$10.84 - $16.55 $110,437 - $168,611	-10,188 Reduced 48.38%	10,872 $123,000
Q4 2021 Feb 14, 2024	BUY	$15.69 - $21.14 $330,431 - $445,208	21,060 New	21,060 $330,000
Q1 2021 Apr 26, 2021	BUY	$13.42 - $20.28 $178,942 - $270,413	13,334 Added 172.59%	21,060 $316,000
Q2 2020 Aug 10, 2020	BUY	$9.66 - $12.02 $74,633 - $92,866	7,726 New	7,726 $88,000

161

45.2M

165K

33.6K

Ticker VNDA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,561,500
Market Cap $247M
Description
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs. The company's marketed products include HETLIOZ for the treatment of non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its products under developme...

Get notified when there are updates to the investment portfolio of Kbc Group Nv, based on Form 13F filings with the SEC.

Stay updated on Kbc Group Nv with notifications on news.